Other sites include pY62/63 of the tyrosine phosphatase Shp2; Shp2 knockdown has been reported to increase cellular sensitivity to gefitinib in EGFR-TKI-resistant lung cancer cells42. The gene discussed is EGFR; the disease is lung cancer.